AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines
Objective: Multiple myeloma (MM) is the clonal proliferation of neoplastic plasma cells in the bone marrow. Although bortezomib (BTZ) is a crucial drug for the treatment of MM, drug resistance is a major problem. OncomiR-19a plays an oncogenic role in many cancers, including MM; however, the functio...
Saved in:
Main Authors: | Azam Kazemi, Saeid Abroun, Masoud Soleimani |
---|---|
Format: | article |
Language: | EN |
Published: |
Royan Institute (ACECR), Tehran
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/d0a174c47a674058bb15b47c9426b3fd |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
by: Paweł Robak, et al.
Published: (2021) -
Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
by: Yuki Fujimoto, et al.
Published: (2021) -
AL amyloidosis in the Chilean public health system: a pending debt. Multicenter study of the Chilean Monoclonal Gammopathies Cooperative Group
by: Peña,Camila, et al.
Published: (2019) -
Prognostic impact of renal failure recovery in patients with newly diagnosed multiple mieloma
by: PEÑA,CAMILA, et al.
Published: (2019) -
Mieloma múltiple en Chile: Respuesta a tratamiento en pacientes con mieloma múltiple elegibles para trasplante autólogo de progenitores hematopoyéticos
by: PEÑA,CAMILA, et al.
Published: (2019)